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Abstract 
 
Objective  To assess the effects of empagliflozin, a selective SGLT2 inhibitor, on broad 
biological systems through proteomics. 
Research Design and Methods  3,713 proteins were quantified using aptamer-based proteomics 
in 144 paired plasma samples obtained from 72 participants across the spectrum of glucose 
tolerance, before and after 4 weeks of empagliflozin 25 mg/day.  Biology of the plasma proteins 
significantly changed by empagliflozin (at false discovery rate-corrected p<0.05) was discerned 
through Ingenuity Pathway Analysis. 
Results  Empagliflozin significantly affected levels of 43 proteins, 6 related to cardiomyocyte 
function (fatty acid binding protein 3 and 4 (FABPA), neurotrophic receptor tyrosine kinase 
(NTRK2), renin, thrombospondin-4, and leptin receptor), 5 to iron handling (ferritin heavy chain 1, 
transferrin receptor protein 1 (TFRC), neogenin, growth differentiation factor 2 (GDF-2), and ß2-
microglobulin) and 1 to spingosine/ceramide metabolism (neutral ceramidase), a known pathway of 
cardiovascular disease.  Among the protein changes achieving the strongest statistical significance, 
insulin-like binding factor protein-1 (IGFBP-1), transgelin-2, FABPA, growth differentiation factor-
15 (GDF15), and sulphydryl oxidase 2 precursor (QSOX2) were increased, while ferritin, 
thrombospondin-3, and REarranged during Transfection (RET) were decreased by empagliflozin 
administration  
Conclusion  SGLT2 inhibition is associated, directly or indirectly, with multiple biological 
effects, including changes in markers of cardiomyocyte contraction/relaxation, iron handling, and 
other metabolic and renal targets.  The most significant differences were detected in protein species 
(GDF15, ferritin, IGFBP-1 and FABP) potentially related to the clinical and metabolic changes that 
were actually measured in the same patients.  These novel results may inform further studies, using 
targeted proteomics and a prospective design.  
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Introduction 
   
Sodium-glucose cotransporter-2 (SGLT2) is a transmembrane protein encoded by genes of the 
SLC5A family (1).  SGLT2 is a high capacity, low-affinity transporter almost exclusively expressed 
on the luminal side of the S1 segment of the proximal renal tubule.  Its function is to reabsorb 
glucose and sodium from the glomerular filtrate into the circulation.  Convincing evidence shows 
that SGLT2 is functionally overactive in patients with type 2 diabetes (T2D), in whom it therefore 
contributes to the hyperglycemia (2,3).  SGLT2 inhibition results in urinary excretion of glucose, 
sodium, and water, leading to hemodynamic changes as well as glycemic improvements in patients 
with T2D (1).  SGLT2 inhibitors (SGLT2i) have been developed as glucose-lowering drugs for the 
treatment of T2D.  Somewhat unexpectedly, large cardiovascular (CV) safety trials testing SGLT2i 
against placebo in T2D patients at high CV risk have consistently demonstrated clinically relevant 
benefit for both cardiovascular and renal outcomes (4-6).  This has led to changes in clinical 
recommendations and practice (7,8).  As the glucose-lowering efficacy of SGLT2i is generally 
modest (i.e., HbA1c reductions in the range 0-6-0.8% (9)), it is widely believed that mechanisms 
other than (or in addition to) glycemic control must be at work to explain the cardiovascular and 
renal protection of SGLT2i.  The recently published DAPA-HF results also suggest that SGLT2i 
lessen risk of heart failure by mechanisms independent of glycemia since benefits were identical in 
those with and without diabetes (10).  Multiple hypotheses have been advanced, not necessarily 
exclusive of one another.  Thus, SGLT2i-induced natriuresis and osmotic diuresis with blood 
volume contraction may be responsible for the reduction in blood pressure and arterial stiffness, 
which can improve cardiac function by decreasing both pre- and afterload (11,12).  Also, SGLT2i 
may optimize tissue energy metabolism and mitochondrial bioenergetics in impaired heart and 
kidney by supplying an excess of ‘thrifty’ substrates (e.g., ketones) (13).  Reduction of uricemia 
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(14), modulation of the tubulo-glomerular feedback (15), and lowering of inflammation and fibrosis 
biomarkers (16) are additional putative contributors to reported benefits.   
From the in vivo mechanistic information so far gathered, it is likely that the primary action of 
SGLT2i on the proximal renal tubule induces a range of physiological consequences in several 
domains of bodily functions.  Proteomics is a useful approach to explore canonical biological 
pathways in a hypothesis-free fashion (17).  This prompted us to screen the plasma proteome of 
individuals with T2D or impaired glucose tolerance (IGT) receiving SGLT2i treatment by applying 
a large-scale version of an aptamer-based multiplex proteomics platform (SOMAscan) to quantify 
plasma proteins (18). 
 
Methods 
 
Study population A total of seventy-two participants (25 women and 47 men) were recruited 
into the study (Table S1).  Of these, 61 were patients with T2D (29 were drug-naïve or off any 
glucose-lowering agent for at least 12 weeks, and 32 were on a stable dose of metformin of ≥1,500 
mg/day for at least 12 weeks).  Inclusion criteria were either sex, age >18 years, body mass index 
(BMI) 20–40 kg/m2, HbA1c 6.5–10.5% (48-91 mmol/mol), and estimated glomerular filtration rate 
(eGFR) >60 ml.min-1.1.73m-2 (by the CKD-EPI equation (19)).  Duration of diabetes was <1 year in 
3%, <5 years in 18%, <10 years in 26%, and ≥10 years in 19% of the patients.  Exclusion criteria 
were: history of malignancy in the last 5 years; significant cardiovascular disorder within last 6 
months; pregnancy or women expecting to conceive within the study duration; bariatric surgery 
within the past 2 years; treatment with antiobesity drugs in the last 3 months; neurogenic bladder 
disorders; ALT and AST >3.0 x ULN; changes in thyroid hormone dosage within 6 weeks or any 
other endocrine disease except T2D; alcohol or drug abuse.  Detailed metabolic analysis of these 
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patients has been published previously (20).  Eleven subjects with IGT (by ADA criteria) were 
included; their anthropometric and metabolic characteristics have been reported (21).   
Protocol  One hundred and fourty-four fasting EDTA plasma samples were obtained from the 
participants at baseline and after 4 weeks of treatment with 25 mg/day empagliflozin.  The modified 
aptamer binding reagents, SomaScan assay and its performance characteristics have previously been 
described (22-25).  In brief, each of the individual proteins measured has its binding reagent made 
of chemically modified DNA, referred to as a modified aptamer.  Each plasma sample was 
incubated with the mixture of modified aptamers to generate modified aptamer-protein complexes 
under equilibrium conditions.  Unbound modified aptamers and unbound or nonspecifically bound 
proteins were eliminated by 2 bead-based immobilization steps.  After elution of the modified 
aptamers from the target protein, the fluorescently labeled modified aptamers were directly 
quantified on hybridization array (Agilent Technologies).  Calibrators were included so that the 
degree of fluorescence was a consistent reflection of protein concentration.  Protein concentration 
was expressed as relative fluorence units (RFU).  All samples were placed randomly on 96-well 
plates, run in a single batch, and normalized against protein calibrator samples included on each 
plate.  Technicians were blinded to the before and after status of samples.  Details of scaling, 
normalization and control of batch effects are given in (26).  Median intra- and interassay 
coefficients of variation are ~5% (25).  A total of 4,005 proteins were measured, 292 of them failed 
to pass SomaLogic’s quality control metrics, leaving 3,713 proteins for analysis.  Differences 
between the baseline and 4-week samples were expressed as log2 ratios for each of the proteins 
measured. 
Plasma glucose and creatinine concentrations were measured by standard laboratory methods.  
Creatinine clearance was measured on carefully collected urine samples as the ratio of urinary 
creatinine excretion and plasma creatinine levels.   
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Statistical analysis  Differences between on-treatment and baseline values were analyzed by the 
Wilcoxon signed-rank test for paired comparisons in 3,713 protein measurements; p values were 
corrected for multiple comparisons using both the Bonferroni family-wise error rate correction and 
the Benjamini-Hochberg false discovery rate (FDR) correction.  Proteins with an FDR-adjusted 
value of p<0.05 were considered statistically significant for inclusion in the pathway analysis.  
Ingenuity Pathway Analysis (IPA) was used to cluster differentially expressed proteins after 4 
weeks of treatment compared with baseline into pathways and functional groups.  For those 
modified aptamers that had multiple Uniprot identifications associated with one result, only the first 
listed Uniprot identification was used in pathway analysis (27).  The Fisher right-tailed exact test 
was used to calculate a p value to determine the probability that the association of the differently 
expressed proteins in the measured data set and the pathway is explained by chance alone.    
Correction for changes in creatinine clearance was carried out using a mixed model with patient ID 
as a random effect.   
 
Results 
 
As expected, in the whole group of subjects 4 weeks of treatment resulted in significant 
decreases of body weight and body, HbA1c, fasting glycemia and creatinine clearance 
(Supplemental Table S1). 
Of the 3,713 proteins measured, 21 were not recognized by IPA, and the remainder were used 
as background reference.  No statistically significant differences in the within-subject responses 
were seen between baseline and treatment in the 3 groups of participants (drug-naïve T2D, 
metformin-treated T2D, and IGT) (r2 = 0.035, p=0.22).  There were also no discernible differences 
on an individual protein target level, as evidenced by univariate Kruskal-Wallis tests, on the within-
subject (baseline minus treatment) differences (e.g., Figure 1).  Therefore, in all subsequent 
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analyses the three groups were treated as one. 
On an initial screen using an FDR p value ≤0.05 corrected for 3,713 dimensions, 44 proteins 
were associated with a significant change between baseline and treatment (16 reaching a Bonferroni 
p value<0.05) (Table 1).  Pathway analysis grouped these proteins into biological pathways ranging 
from iron handling and cardiomyocyte contractility and relaxation to lipid and glucose metabolism 
(Figure 2).  The target proteins – and their genes – that showed the largest change with treatment 
(i.e., a percent change lower than -15% or higher than +19%) with an FDR p<0.05 (model 1) are 
listed in Table 2. 
Creatinine clearance was mildly but significantly reduced after 4 weeks of empagliflozin 
treatment (Table 1).  This change may bias the assessment of treatment effects because of 
accumulation of waste products in the blood.  The analysis was therefore repeated after adjustment 
for individual changes in creatinine clearance (model 2).  Several proteins that were significant (at 
the FDR p<0.05 level) in model 1 lost significance.  In particular, seven protein targets with p 
values <0.05 moved to p values >0.20 after the correction for creatinine clearance: cystatin-SN 
(CST1.5459.33.3), guanylate cyclase activator 2B (uroguanylin, GUCA2B.6223.5.3), trefoil factor 
3 (TFF3.4721.54.2), C-C motif chemokine 15 (CCL15.3509.1.1), thrombospondin-4 
(THBS4.3340.53.1), renin (REN.3396.54.2), and neutral ceramidase (ASAH2.3212.30.3). 
The results of model 2 are given in Table S2 in descending order of FDR corrected p values, 
down to a p value <0.10.   
 
Discussion 
 
Empagliflozin treatment for 4 weeks altered the proteomic profile in the plasma of individuals 
with T2D.  Among the proteins that changed in response to treatment, pathway analysis indicated 
that their biological roles pertained to lipid and glucose metabolism, iron handling, cardiomyocyte 
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function (contraction and relaxation), cytokines, and molecular transport.  In accord with previous 
metabolic results in these subjects (21,28), there was no formally tested difference across 
background antihyperglycemic treatment (metformin or none) or glucose tolerance status (T2D vs 
IGT).  This made it possible to analyze all available data as one set. 
Circulating protein concentrations are the net balance of release into the bloodstream (resulting 
from changes in gene expression/transcription and/or cellular secretion/shedding) and removal from 
the plasma (by degradation or excretion).  Empagliflozin, like other SGLT2i, causes a reduction in 
eGFR, which persists as long as treatment continues and is reversed on stopping it (4,9,14).  eGFR 
adjustment of our patients’ proteomic profile was therefore necessary to protect against bias 
introduced by hemodynamic and filtration changes.  It is of interest that with eGFR adjustment 7 
proteins lost strength of association with treatment.  Among them is cystatin, a clinical marker of 
GFR, and 3 other proteins – renin, guanylate cyclase activator 2B, and trefoil factor 3 – that also are 
influenced by changes in GFR.  This finding, along with the use of nonparametric testing and 
stringent multicomparison p-value restriction, adds confidence in the reliability of the remaining 
observed treatment-induced protein changes. 
Among the plasma protein changes achieving the strongest statistical significance, IGFBP-1, 
transgelin-2, FABPA, GDF15, and QSOX2 were increased by empagliflozin, while ferritin, 
thrombospondin-3, and RET were decreased.  Interpretation of the biological significance of such 
changes in the context of the biochemical modifications observed in vivo must be done with caution.  
In fact, ingenuity pathway analysis almost invariably suggests that any given protein plots on to 
several different pathways.  Thus, IGFBP-1 – produced mainly by the liver in response to nutritional 
stimuli – acts as a transport protein of IGF to prolong its half-life, guide a tissue-specific 
localization, and modulate its actions (29) (Figure S1).  A strong, consistent association between 
circulating IGFBP-1 and insulin sensitivity has been reported in diverse populations (30).  
 9 
Furthermore, plasma IGFBP-1 levels are inversely correlated with leptin levels (31).  In T2D 
patients, SGLT2i treatment reduces visceral fat (32) and ameliorates insulin resistance (20,33,34).  
This may suggest a causal path whereby empagliflozin improves insulin resistance through 
upregulation of IGFBP-1.  However, IGFBP-1 is also involved in RXR activation and estrogen 
receptor signaling (33), vascular function (35), cell migration via integrin (36), and pancreatic ß-cell 
regeneration (37).  Therefore, additional links to IGFBP-1 may emerge as the range of physiological 
consequences of SGLT2 therapy in patients with diabetes is expanded and physiologically 
explained.  
Serum ferritin, a key parameter of iron homeostasis (Figure S2), also is a well-known marker 
reflecting insulin resistance and liver fat accumulation (38).  The reduced ferritin levels after 
empagliflozin (-34%) resonate with the alleviation of hepatic steatosis reported in several studies of 
SGLT2i (39,40).  On the other hand, the reduction in ferritin may be linked with the observed (mild 
and transient) increase in erythropoietin (21), reflecting a boost in erythropoiesis (41). 
GDF15, a member of the transforming growth factor-β (TGF-β) superfamily, is a myomitokine 
whose induction in mice protects against the onset of obesity and insulin resistance by promoting 
oxidative function and lipolysis in liver and adipose tissue (42).  GDF15 has recently received 
interest as a potential therapeutic target in obesity as well as cancer-associated cachexia (43).  
Recently, glial-cell-derived neurotrophic factor receptor α-like (GFRAL) was identified as a specific 
receptor of GDF15, requiring the co-receptor RET to execute intracellular signaling (44,45).  In the 
current data, the joint increase in GDF15 and decrease in RET (Table 3) might stand for a 
coordinated stress-like response to empagliflozin-induced weight loss (41), and/or such changes 
may contribute to the weight loss associated with SGLT2i therapy.  As a general tissue stress and 
injury signal, GDF15 has been reported to be a predictive biomarker for cardiovascular events and 
death in individuals with dysglycemia (42).   It is intriguing that in the large cardiovascular 
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outcomes trial, ORIGIN, GDF15 was found to be increased in patients with T2D on treatment with 
metformin (48).  
Fatty acid-binding protein 4 (FABP4) is primarily located in adipocytes and macrophages (49).  
It has been implicated in the pathogenesis of insulin resistance and atherosclerosis (50).  FABP4 is 
released from adipocytes in a non-classical pathway associated with lipolysis.  In the patients in the 
present study, empagliflozin stimulated lipolysis through a reduction in plasma insulin 
concentrations (20).  The observed increase in plasma FABP4 can therefore be plausibly connected 
with an increased lipolysis.   
The thrombospondin family consists of adhesive glycoproteins that mediate cell-to-cell and 
cell-to-matrix interactions (51).  Thrombospondin-3, which is abundant in muscle and kidney, is 
linked to the endoplasmic reticulum (ER) stress response (52).  Presumably, abatement of ER stress 
by SGLT2 inhibition may relate to the 16% decrement in thrombospondin-3 levels found in the 
present study. 
This exploratory study has limitations. The sample size was modest, with no placebo control, 
and treatment only lasted 4 weeks.  We therefore opted for a conservative analysis of the proteomic 
data so as to down-rank random variation between baseline and treatment.  That noted, we did see 
the expected changes in glycemia, weight and eGFR, and in surrogates of liver fat, lending external 
validity to the findings.  We cannot exclude the possibility that the proteome might change further 
with prolonged treatment, nor can we extrapolate the findings in our cohort of well-controlled 
patients free of macro- and microvascular complications to the participants of the EMPAREG 
OUTCOME trial (4), who had established cardiovascular disease.  While vascular and/or renal 
complications are likely to add their specific proteomic signatures, the protein panel here described 
may reflect early effects of SGLT2 inhibition.  
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In conclusion, treatment with empagliflozin in patients with T2D was associated with a shift in 
the plasma proteome.  The most significant differences were detected in protein species potentially 
related to the clinical and metabolic changes that were actually measured in the same patients (20).  
Novel results on GDF15, ferritin, IGFBP-1 and FABP should stimulate further studies, using 
targeted proteomics and a prospective design.  At present, our findings represent the first 
hypothesis-free evidence that SGLT2 inhibition affects the plasma proteome in a biologically 
plausible fashion.   
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Table 1 – Top protein targets with an FDR p value <0.05. 
 
 
 
Target Entrez Gene  UniProt 
log2 fold-
change 
p value Bonferroni p  FDR 
IGFBP-1  IGFBP1 P08833 0.53 2.57E-11 9.54E-08 6.72E-08 
Ferritin  FTH1 FTL P02794 P02792 -0.60 3.62E-11 1.34E-07 6.72E-08 
DSC2  DSC2 Q02487 0.11 2.32E-08 8.62E-05 1.78E-05 
FABPA  FABP4 P15090 0.30 2.39E-08 8.90E-05 1.78E-05 
FABP  FABP3 P05413 0.23 4.00E-08 0.00015 2.48E-05 
HE4  WFDC2 Q14508 0.14 7.50E-08 0.00028 3.98E-05 
TSP3  THBS3 P49746 -0.26 3.64E-07 0.0014 0.00016 
TFF3  TFF3 Q07654 0.12 3.86E-07 0.0014 0.00016 
MIC-1  GDF15 Q99988 0.27 5.33E-07 0.0020 0.00020 
QSOX2  QSOX2 Q6ZRP7 0.26 2.15E-06 0.0080 0.00073 
TMEDA  TMED10 P49755 0.14 3.71E-06 0.014 0.0011 
Renin  REN P00797 0.20 4.14E-06 0.015 0.0011 
FAM3B  FAM3B P58499 0.13 4.61E-06 0.017 0.0011 
TR  TFRC P02786 0.17 4.99E-06 0.019 0.0012 
MRC2  MRC2 Q9UBG0 -0.19 5.86E-06 0.022 0.0013 
MIP-5  CCL15 Q16663 0.11 9.53E-06 0.035 0.0020 
BSP  IBSP P21815 0.20 2.35E-05 0.088 0.0042 
NEO1  NEO1 Q92859 -0.11 2.35E-05 0.088 0.0042 
Leptin R  LEPR P48357 0.09 3.13E-05 0.12 0.0052 
PTPRU  PTPRU Q92729 -0.17 3.25E-05 0.12 0.0052 
Trypsin  PRSS1 P07477 0.15 8.26E-05 0.31 0.013 
IL-1 sRII  IL1R2 P27930 -0.09 0.00011 0.42 0.016 
ITIH3  ITIH3 Q06033 0.10 0.00011 0.42 0.016 
CYTN  CST1 P01037 0.13 0.00016 0.58 0.022 
OMD  OMD Q99983 -0.16 0.00016 0.61 0.022 
MINP1  MINPP1 Q9UNW1 0.09 0.00017 0.63 0.022 
PAPP-A  PAPPA Q13219 0.16 0.00019 0.71 0.024 
RNAS6  RNASE6 Q93091 0.13 0.00022 0.82 0.026 
SECTM1  SECTM1 Q8WVN6 0.15 0.00024 0.87 0.027 
GDF2  GDF2 Q9UK05 -0.19 0.00024 0.89 0.027 
CYTT  CST2 P09228 0.09 0.00025 0.91 0.027 
ß2-Microglobulin  B2M P61769 0.13 0.00025 0.93 0.027 
RNAS4  RNASE4 P34096 0.07 0.00027 1 0.028 
Transgelin-2  TAGLN2 P37802 0.55 0.00035 1 0.035 
CBLN4  CBLN4 Q9NTU7 -0.12 0.00035 1 0.035 
CD59  CD59 P13987 0.08 0.00036 1 0.035 
ASAH2  ASAH2 Q9NR71 -0.16 0.00038 1 0.035 
TSP4  THBS4 P35443 -0.23 0.00041 1 0.037 
Collectin Kidney 1  COLEC11 Q9BWP8 -0.10 0.00043 1 0.037 
Afamin  AFM P43652 -0.10 0.00043 1 0.037 
SIAT9  ST3GAL5 Q9UNP4 0.12 0.00050 1 0.042 
RET  RET P07949 -0.29 0.00052 1 0.043 
TrkB NTRK2 Q16620 -0.11 0.00056 1 0.046 
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Table 2 – Protein targets with a log2 fold-change absolute value >0.25 (i.e., % change 
lower than -15% or higher +19%) and an FDR p<0.05. 
 
  
Target  Gene  % change p Bonferroni p FDR 
IGFBP-1 IGFBP1 +44 2.57E-11 6.72E-08 9.54E-8 
Ferritin FTH1 
FTL 
-34 3.62E-11 6.72E-08 1.34E-07 
FABPA FABP4 +23 2.39E-08 1.78E-05 8.90E-05 
Thrombospondin-3 THBS3 -16 3.64E-07 0.00016 0.0014 
GDF15 GDF15 +21 5.33E-07 0.00020 0.0020 
QSOX2 QSOX2 +20 2.15E-06 0.00073 0.0080 
Transgelin-2 TAGLN2 +46 0.00035 0.035 1 
RET RET -18 0.00052 0.043 1 
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Table S1 – Anthropometric and metabolic characteristics of the study 
subjects.* 
 
 Baseline 4 weeks p 
Age (years) 60 ± 9 - - 
Body weight (kg) 96 ± 16 94 ± 16 <0.0001 
Body mass index  (kg.m-2) 31.6 ± 4.6 31.1 ± 4.5 <0.0001 
HbA1c (%) 7.2 ± 1.0 6.8 ± 0.8 <0.0001 
Fasting plasma glucose (mmol/L) 7.5 ± 1.6 6.4 ± 1.0 <0.0001 
Creatinine clearance (ml.min-1.1.73m-2) 101 ± 24 97 ± 24 0.0023 
*entries are mean ± SD; p values are from Wilcoxon 
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Table S2 – Protein targets with an FDR p<0.10 adjusted for creatinine clearance. 
 
  
TARGET Gene  UniProt p Bonferroni p FDR 
Ferritin  FTH1 FTL 
P02794 
P02792 
1.44E-12 5.35E-09 5.22E-09 
IGFBP-1  IGFBP1 P08833 2.81E-12 1.04E-08 5.22E-09 
FABPA  FABP4 P15090 1.46E-06 0.0054 0.0012 
FABP  FABP3 P05413 1.66E-06 0.0062 0.0012 
HE4  WFDC2 Q14508 2.03E-05 0.075 0.013 
BSP  IBSP P21815 2.65E-05 0.098 0.014 
MIC-1  GDF15 Q99988 3.81E-05 0.14 0.018 
QSOX2  QSOX2 Q6ZRP7 4.99E-05 0.19 0.021 
TR  TFRC P02786 5.78E-05 0.22 0.021 
PTPRU  PTPRU Q92729 0.00011 0.42 0.038 
FAM3B  FAM3B P58499 0.00012 0.46 0.038 
TMEDA  TMED10 P49755 0.00018 0.65 0.047 
TFF3  TFF3 Q07654 0.00018 0.65 0.047 
GDF2  GDF2 Q9UK05 0.00025 0.93 0.062 
S22AG  SLC22A16 Q86VW1 0.00028 1 0.064 
DSC2  DSC2 Q02487 0.00040 1 0.087 
SLIK3  SLITRK3 O94933 0.00048 1 0.099 
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Figure 1 – Boxplots of values (as log10 RFU) of 6 target proteins in subjects with impaired glucose 
tolerance (IGT), drug-naïve type 2 diabetes (T2D), or metformin-treated type 2 diabetes (T2Dm) 
before (b) and after (a) treatment with empagliflozin. 
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Figure 2 – Distribution of the top 56 treatment-induced proteins into biological categories by 
pathway analysis.  
 23 
 
Figure S1 – Network centered on IGFBP-1 of proteins significantly altered by empagliflozin. 
Nodes represent gene symbol name, corresponding to protein measured.  The degree of intensity of 
the node color (red) indicates degree of significance of p-value.  Nodes not colored are proteins 
either not significant or not measured.  The lines correspond to the implicated function of the given 
proteins according to the IPA knowledge bank.  The node shapes denote enzyme ( ), transporter (
), growth factor ( ), transmembrane receptor ( ), peptidase ( ), phosphatase ( ), kinase ( ), 
transcription regulator ( ), translation regulator ( ), ion channel ( ), cytokine ( ), chemical (
), ligand dependent nuclear receptor ( ) and other ( ).   
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Figure S2 – Proteins significantly altered by empagliflozin associated with iron homeostasis. 
Nodes represent gene symbol name, corresponding to protein measured.  The degree of intensity of 
the node color (red) indicates degree of significance of p-value.  The dashed lines correspond to the 
implicated function of the given proteins according to the IPA knowledge bank. The node shapes 
denote cytokine ( ), transmembrane receptor ( ), transporter ( ), transcription regulator ( ), and 
enzyme ( ). 
 
